Alexion Pharmaceuticals Inc.
http://www.alexion.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alexion Pharmaceuticals Inc.
Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Galenica Struggles In Switzerland As Pandemic Paralyzes Sales
Galenica struggled to keep up with OTC market growth in Switzerland as the COVID-19 outbreak severely hampered its sales in the opening six months of the year.
Keeping Track: The Breakthrough Designations Of Summer Eschew Phase I
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
- Enobia Pharma Corp.
- Portola Pharmaceuticals, Inc. (PTLA)
- Synageva BioPharma Corp.
- Syntimmune, Inc.
- Taligen Therapeutics, Inc.
- Wilson Therapeutics AB